Clinical Trial Update: Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer [Phase 2]

View source ↗

Summary

This clinical trial update reports Phase 2 results for pemetrexed as second-line therapy in hormone-refractory prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Alimta (pemetrexed)

Snippet

Sponsor: Christopher Sweeney, MBBS | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-07-29